Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 ...

(IN BRIEF) Equinor has announced the start of the first tranche of its 2025 share buy-back programme, set to repurchase up to USD 396 million worth of shares from the market, part of a broader ...